...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: AMRN is up big time this am

primarily because of its cost effectiveness disclosed in an abstract entitled : 

Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT,” in connection with the 2019 Scientific Sessions of the American Heart Association (AHA), scheduled for November 16 – 18 in Philadelphia, PA. William S. Weintraub, M.D., director of Outcomes Research with MedStar Cardiovascular Research Network, and lead author of the analysis, is scheduled to present the results in more detail at AHA on Saturday, November 16, at 7:30 a.m.

 

Share
New Message
Please login to post a reply